Analysts expect that Retrophin Inc (NASDAQ:RTRX) will post earnings of ($0.24) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Retrophin’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.22). Retrophin reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 200%. The business is scheduled to issue its next earnings report on Thursday, August 3rd.
On average, analysts expect that Retrophin will report full-year earnings of ($1.02) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($0.89). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.20) per share, with EPS estimates ranging from ($1.61) to ($0.79). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Retrophin.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.23. The firm had revenue of $33.62 million during the quarter, compared to the consensus estimate of $36.20 million. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the business posted $0.14 earnings per share.
A number of analysts recently commented on RTRX shares. BMO Capital Markets dropped their price target on shares of Retrophin from $46.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, March 2nd. Zacks Investment Research cut shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, William Blair restated an “outperform” rating on shares of Retrophin in a research note on Thursday, April 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $32.25.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/06/16/retrophin-inc-rtrx-expected-to-announce-earnings-of-0-24-per-share-updated-updated-updated.html.
Several hedge funds have recently made changes to their positions in the stock. Scopia Capital Management LP acquired a new stake in shares of Retrophin during the third quarter worth approximately $95,180,000. Bogle Investment Management L P DE boosted its stake in shares of Retrophin by 458.5% in the fourth quarter. Bogle Investment Management L P DE now owns 200,196 shares of the biopharmaceutical company’s stock worth $3,789,000 after buying an additional 164,349 shares during the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Retrophin during the fourth quarter worth approximately $1,041,000. Boston Advisors LLC boosted its stake in shares of Retrophin by 24.4% in the first quarter. Boston Advisors LLC now owns 230,005 shares of the biopharmaceutical company’s stock worth $4,246,000 after buying an additional 45,050 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Retrophin during the third quarter worth approximately $1,676,000.
Shares of Retrophin (NASDAQ:RTRX) traded up 1.13% during midday trading on Tuesday, reaching $17.91. 193,475 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $18.31 and a 200 day moving average price of $19.44. Retrophin has a 12 month low of $15.40 and a 12 month high of $24.57. The firm’s market cap is $683.68 million.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc and related companies with MarketBeat.com's FREE daily email newsletter.